 Stakeholder Call Thursday, May 25: A New Way Forward for Cannabidiol and Other Hemp Products
The U.S. Food and Drug Administration's Stakeholder Engagement Staff invites you to an important stakeholder call to provide information about FDA's conclusion that a new regulatory pathway is needed to provide appropriate regulatory oversight for cannabidiol products. The call will be held on Thursday, May 25, 2023, at 3:00 PM ET.
Speakers will include Janet Woodcock, M.D., Principal Deputy Commissioner, Norman Birenbaum, Senior Public Health Advisor, and Patrick Cournoyer, Ph.D., Senior Science Advisor.
This call is intended for industry, trade associations, legal and policy organizations.
Register in advance for this webinar:
https://fda.zoomgov.com/webinar/register/WN_dHGZkCtaS3SmccFXaKszDg
After registering, you will receive a confirmation email containing information about joining the webinar. If you would like to submit a question for the panelists, please do so by May 24, 2023.
For background: See https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol
For Immediate Release: January 26, 2023
Statement From: Janet Woodcock, M.D., Principal Deputy Commissioner - Office of the Commissioner
FDA Concludes that Existing Regulatory Frameworks for Foods and Supplements are Not Appropriate for Cannabidiol, Will Work with Congress on a New Way Forward
Given the growing cannabidiol (CBD) products market, the FDA convened a high-level internal working group to explore potential regulatory pathways for CBD products. Today we are announcing that after careful review, the FDA has concluded that a new regulatory pathway for CBD is needed that balances individuals’ desire for access to CBD products with the regulatory oversight needed to manage risks. The agency is prepared to work with Congress on this matter.
Today, we are also denying three citizen petitions that had asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.
FDA values stakeholder engagement and, for the short term, has two ways for stakeholders to provide their input regarding this announcement.
- FDA established docket FDA-2019-N-1482 that is open for public comment. Stakeholders are encouraged to submit either electronic or written comments.
- Over the next several months, FDA plans to host a series of stakeholder engagements with the goal of learning more from a broad range of stakeholders.
Thank you for your support of FDA and its mission.
Related Materials
About US
The Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations.
|
